Clinical Trials Using Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118

Clinical trials are research studies that involve people. The clinical trials on this list are studying Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • Vaccine Therapy (pTVG-HP DNA Vaccine with or without pTVG-AR DNA Vaccine) and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

    This phase II trial studies how well vaccine therapy (pTVG-HP DNA vaccine with or without pTVG-AR DNA vaccine) and pembrolizumab work in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). The pTVG-HP DNA vaccine and pTVG-AR DNA vaccine are made of DNA (genetic material) that contains genetic code for proteins that are made by the prostate gland. These “DNA vaccines” may strengthen the immune system to fight cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The main purpose of this study is to test the effectiveness of pTVG-HP and pTVG-AR DNA vaccines in combination with pembrolizumab in slowing or stopping the growth of prostate cancer after it has stopped responding to testosterone-lowering therapy.
    Location: 2 locations